MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Craig, P. I.
Right arrow Articles by Farrell, G. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Craig, P. I.
Right arrow Articles by Farrell, G. C.

Interferon down regulates the male-specific cytochrome P450IIIA2 in rat liver

PI Craig, I Mehta, M Murray, D McDonald, A Astrom, PH van der Meide and GC Farrell

Department of Medicine, University of Sydney, Westmead Hospital, New South Wales, Australia.

The aim of this study was to clarify the mechanism by which cytochrome P450 (P450)-mediated catalytic activity is decreased following interferon (IFN) administration. Microsomal steroid hydroxylation was assessed to test the hypothesis that IFN selectively decreases the activities of individual P450 isozymes in male rats. Thus, recombinant rat IFN gamma (r-rat IFN gamma) treatment produced 40% and 17% reductions in androst-4-ene-3,17-dione (androstenedione) 6 beta- and 16 beta-hydroxylation, respectively. Androstenedione 16 alpha- and 7 alpha- hydroxylation were unaltered following r-rat IFN gamma treatment. Similar changes in the androstenedione hydroxylation pathways were observed following administration of naturally derived rat IFN alpha/beta. Microsomal levels of P450IIIA2, the male-specific constitutive steroid 6 beta-hydroxylase, were lower after administration of r-rat IFN gamma (42% of control fractions). Furthermore, hepatic P450IIIA2 mRNA was found to be decreased to a similar extent by r-rat IFN gamma. These findings suggest that IFN selectively decreases the content of this isozyme by a mechanism involving altered mRNA regulation. Sex steroids were unlikely to have mediated the decrease in P450IIIA2 levels since serum estradiol and testosterone levels were unchanged by r-rat IFN gamma. In order to determine whether IFN alters the expression of P450IIIA1, a steroid- inducible member of the P450IIIA gene subfamily which is not expressed in untreated rat liver, adult female rats (which lack P450IIIA2) were coadministered pregnenolone 16 alpha-carbonitrile and r-rat IFN gamma. However, IFN failed to impair the induction of androstenedione 6 beta- hydroxylation produced by pregnenolone 16 alpha-carbonitrile. These findings suggest that although IFN decreases the expression of P450IIIA2, it may not down regulate the expression of other steroid- inducible P450IIIA proteins. In view of the existence of human P450IIIA orthologs which catalyze the metabolism of several important therapeutic agents, the findings of this study may help predict possible drug interactions in patients receiving IFN.

Volume 38, Issue 3, pp. 313-318, 09/01/1990
Copyright © 1990 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
H. Kawaguchi, Y. Matsui, Y. Watanabe, and Y. Takakura
Effect of Interferon-{gamma} on the Pharmacokinetics of Digoxin, a P-glycoprotein Substrate, Intravenously Injected into the Mouse
J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 91 - 96.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
K. W. Renton and T. E. Nicholson
Hepatic and Central Nervous System Cytochrome P450 Are Down-Regulated during Lipopolysaccharide-Evoked Localized Inflammation in Brain
J. Pharmacol. Exp. Ther., August 1, 2000; 294(2): 524 - 530.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
M. I. Guillén, M. T. Donato, R. Jover, J. V. Castell, R. Fabra, R. Trullenque, and M. J. Gómez-Lechón
Oncostatin M Down-regulates Basal and Induced Cytochromes P450 in Human Hepatocytes
J. Pharmacol. Exp. Ther., April 1, 1998; 285(1): 127 - 134.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
S. Wu, W. Chen, E. Murphy, S. Gabel, K. B. Tomer, J. Foley, C. Steenbergen, J. R. Falck, C. R. Moomaw, and D. C. Zeldin
Molecular Cloning, Expression, and Functional Significance of a Cytochrome P450 Highly Expressed in Rat Heart Myocytes
J. Biol. Chem., May 9, 1997; 272(19): 12551 - 12559.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. T. Donato, M. I. Guillén, R. Jover, J. V. Castell, and M. J. Gómez-Lechón
Nitric Oxide-Mediated Inhibition of Cytochrome P450 by Interferon-gamma in Human Hepatocytes
J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 484 - 490.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
O. Khatsenko and Y. Kikkawa
Nitric Oxide Differentially Affects Constitutive Cytochrome P450 Isoforms in Rat Liver
J. Pharmacol. Exp. Ther., March 1, 1997; 280(3): 1463 - 1470.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1990 by the American Society for Pharmacology and Experimental Therapeutics